Aura Biosciences (NASDAQ:AURA) Stock Rating Upgraded by Zacks Investment Research

Zacks Investment Research upgraded shares of Aura Biosciences (NASDAQ:AURAGet Rating) from a sell rating to a hold rating in a report published on Thursday, Zacks.com reports.

According to Zacks, “Aura Biosciences Inc. is a clinical-stage oncology company developing a novel technology platform based on virus-like drug conjugates to target and destroy cancer cells selectively while activating the immune system. The company’s lead product candidate includes AU-011. Aura Biosciences Inc. is based in CAMBRIDGE, Mass. “

NASDAQ:AURA opened at $17.85 on Thursday. Aura Biosciences has a 52 week low of $13.50 and a 52 week high of $26.16. The company’s 50-day simple moving average is $19.80.

Several large investors have recently bought and sold shares of the company. Matrix Capital Management Company LP purchased a new position in Aura Biosciences in the 4th quarter valued at about $69,837,000. Medicxi Ventures Management Jersey Ltd purchased a new position in Aura Biosciences in the 4th quarter valued at about $51,617,000. Citadel Advisors LLC purchased a new position in Aura Biosciences in the 4th quarter valued at about $37,318,000. Adage Capital Partners GP L.L.C. purchased a new position in Aura Biosciences in the 4th quarter valued at about $21,318,000. Finally, BlackRock Inc. purchased a new position in Aura Biosciences in the 4th quarter valued at about $4,055,000. Hedge funds and other institutional investors own 46.58% of the company’s stock.

About Aura Biosciences (Get Rating)

Aura Biosciences, Inc operates as a biotechnology company that develops therapies to treat cancer. The company develops virus-like drug conjugates (VDC) technology platform to treat tumors of high unmet need in ocular and urologic oncology. Its AU-011, a VDC candidate, is being developed for the first line treatment of primary choroidal melanoma, a rare disease with no drugs approved.

Featured Stories

Get a free copy of the Zacks research report on Aura Biosciences (AURA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Aura Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aura Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.